CORRECTION: Omixon, CHOP to Commercialize New HLA Genotyping Assay for MiSeq | GenomeWeb

This article has been corrected to list all of the genes targeted by the assay. The previous version noted only one of them.

NEW YORK (GenomeWeb) – Bioinformatics software firm Omixon today announced a licensing deal with the Children's Hospital of Philadelphia to commercialize a new next-generation sequencing-based HLA genotyping assay for use on Illumina's MiSeq instrument.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.